EA200301143A1 - Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 - Google Patents

Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6

Info

Publication number
EA200301143A1
EA200301143A1 EA200301143A EA200301143A EA200301143A1 EA 200301143 A1 EA200301143 A1 EA 200301143A1 EA 200301143 A EA200301143 A EA 200301143A EA 200301143 A EA200301143 A EA 200301143A EA 200301143 A1 EA200301143 A1 EA 200301143A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydroxitriptamine
heterocyclilalkoxy
alkylaminobenzenole
alkyltio
ligands
Prior art date
Application number
EA200301143A
Other languages
English (en)
Inventor
Янфанг Ли
Пинг Зоу
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайт filed Critical Уайт
Publication of EA200301143A1 publication Critical patent/EA200301143A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение предлагает соединение формулы I и его применение для терапевтического лечения расстройств, связанных с 5-HT6 рецептором или на которые влияют 5-HT6 рецепторы.Отчет о международном поиске был опубликован 2002.12.19.
EA200301143A 2001-04-20 2002-04-19 Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 EA200301143A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28564401P 2001-04-20 2001-04-20
PCT/US2002/012512 WO2002085853A2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
EA200301143A1 true EA200301143A1 (ru) 2004-02-26

Family

ID=23095117

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301143A EA200301143A1 (ru) 2001-04-20 2002-04-19 Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6

Country Status (17)

Country Link
US (2) US6831094B2 (ru)
EP (1) EP1392682A2 (ru)
JP (1) JP2004526781A (ru)
KR (1) KR20030088507A (ru)
CN (1) CN1293073C (ru)
AR (1) AR034588A1 (ru)
AU (1) AU2002309585B2 (ru)
BR (1) BR0209047A (ru)
CA (1) CA2444036A1 (ru)
EA (1) EA200301143A1 (ru)
HU (1) HUP0303801A2 (ru)
IL (1) IL158448A0 (ru)
MX (1) MXPA03009490A (ru)
NO (1) NO20034647L (ru)
PL (1) PL366639A1 (ru)
WO (1) WO2002085853A2 (ru)
ZA (1) ZA200309009B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374401A1 (en) * 2002-06-05 2005-10-17 F.Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
KR100755580B1 (ko) * 2002-12-03 2007-09-06 에프. 호프만-라 로슈 아게 Ｃｎｓ-장애의 치료를 위한 5-ｈｔ6-수용체 리간드로서의아미노알콕시인돌
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
BRPI0614341A2 (pt) * 2005-08-15 2011-03-29 Wyeth Corp composto; método para o tratamento de um distúrbio do sistema nervoso central relacionado com o receptor de 5-ht6 ou afetado por ele em um paciente que deste necessite; composição farmacêutica; e processo
BRPI0614343A2 (pt) * 2005-08-15 2011-03-22 Wyeth Corp derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6
AU2007235499A1 (en) * 2006-04-05 2007-10-18 Wyeth Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AU2007255042A1 (en) * 2006-06-01 2007-12-13 Wyeth 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
WO2009006267A2 (en) * 2007-06-28 2009-01-08 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
JP5719028B2 (ja) 2010-10-06 2015-05-13 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274097A (en) * 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
TW288010B (ru) * 1992-03-05 1996-10-11 Pfizer
WO1995003298A1 (en) * 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH0940646A (ja) 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ベンゼン縮合環誘導体又はその塩
GB9523462D0 (en) 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
AU7526798A (en) * 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
EP1196380A2 (en) 1999-07-15 2002-04-17 NPS Allelix Corp. Indoles and indazoles for the treatment of migraine
MXPA03005432A (es) * 2000-12-22 2003-09-10 Wyeth Corp Compuestos de heterociclilindazol y -azaindazol como ligandos de 5-hidroxitriptamina-6.
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸

Also Published As

Publication number Publication date
ZA200309009B (en) 2005-02-21
MXPA03009490A (es) 2004-02-12
WO2002085853A2 (en) 2002-10-31
US20050065185A1 (en) 2005-03-24
CA2444036A1 (en) 2002-10-31
WO2002085853A3 (en) 2002-12-19
PL366639A1 (en) 2005-02-07
CN1293073C (zh) 2007-01-03
HUP0303801A2 (hu) 2004-03-01
NO20034647D0 (no) 2003-10-17
AU2002309585B2 (en) 2008-01-31
AR034588A1 (es) 2004-03-03
NO20034647L (no) 2003-11-20
BR0209047A (pt) 2004-08-10
US20030078286A1 (en) 2003-04-24
US6831094B2 (en) 2004-12-14
EP1392682A2 (en) 2004-03-03
CN1518548A (zh) 2004-08-04
JP2004526781A (ja) 2004-09-02
IL158448A0 (en) 2004-05-12
KR20030088507A (ko) 2003-11-19

Similar Documents

Publication Publication Date Title
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
NO20034289D0 (no) N-(2-aryletylbenzylaminer som antagonister av 5-HT6- reseptoren
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
SE0203713D0 (sv) Novel compounds
IS6922A (is) Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate